Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

New Technology Will Improve Diagnostics Helping Solve Equine Health Mysteries
ewark, Calif. - June 29, 2022 (Investorideas.com Newswire) Prisma Imaging is a biotech company, founded by Michael Silver, that has developed the next generation of equine diagnostic imaging. This technology allows veterinarians access to high-quality images of the entire horse

Nanotechnology Stock News: SureNano Science (CSE: SURE) Signs Licensing Agreement for the State of Oklahoma
Vancouver, British Columbia - June 27, 2021 (Newsfile Corp.) (Investorideas.com Newswire) SURENANO SCIENCE LTD. (CSE: SURE) is pleased to announce that it has signed a licensing agreement with 1150641 BC Ltd. for the exclusive rights to sell and distribute all current and future products developed by 1150641 in the state of Oklahoma.

Biotech Stock News: Kiora Pharmaceuticals (NASDAQ: KPRX) Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
Salt Lake City, Utah - June 27, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) received approval to initiate a first-in-human clinical trial for KIO-301, which is intended to restore lost vision in patients with Retinitis Pigmentosa, a rare, inherited genetic eye disease that causes severe loss of functional vision due to degeneration of the retinal photoreceptors.

Results of Dermatitis Clinical Trial Due This Summer
June 22, 2022 (Investorideas.com Newswire) Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.

New Positive Data Seem to Support Drug Label Expansion
June 22, 2022 (Investorideas.com Newswire) Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too

Biotech Stock News: NurExone Biologic Inc. (TSXV: NRX) to Begin Trading on TSX Venture Exchange and Retains Market Maker
Bnei-Brak, Israel - June 22, 2022 (Newsfile Corp.) (Investorideas.com Newswire) NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) is pleased to announce that, further to its press release of June 15, 2022 announcing the closing of its reverse takeover transaction

New Drug for Heart Failure on Path to Approval, Analyst Says
June 21, 2022 (Investorideas.com Newswire) The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled

Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22
June 15, 2022 (Investorideas.com Newswire) These changes earned Reliq Health Technologies Inc. an upgrade in overall rating by independent investment research and advisory firm, Jefferson Research.

Biopharma Stock News: Day One (NASDAQ: $DAWN) Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma
SOUTH SAN FRANCISCO, Calif. - June 14, 2022 (Investorideas.com Newswire) Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced positive initial data from the first 22 Response Assessment for Neuro-Oncology-evaluable patients enrolled in the ongoing, open-label, single-arm, pivotal Phase 2 FIREFLY-1 clinical trial.

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise
June 13, 2022 (Investorideas.com Newswire) Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

BioHarvest Sciences Inc. Announces Appointment of Gavriel Lambert to the Board of Advisors
Gavriel Lambert's 27 years of investment banking experience, covering the consumer and retail sectors and working on numerous capital markets transactions including IPOs, financings and M&A, will significantly enhance the Board of Advisors. His appointment continues to demonstrate the Company's resolve to partner with top life science and Cannabis companies. Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 30, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") today announced that effective...

GoodCap Pharmaceuticals Announces Publication of International Patent Application
Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - GoodCap Pharmaceuticals Inc. ("GoodCap"), a biopharmaceutical company developing low-dose psychedelic therapies, is pleased to announce publication of its international patent application (PCT/IB2021/059301) (the "Patent"). The Patent covers the administration of 5HT2A receptor agonists, which include psychedelic molecules, combined with potentiator molecules, to target chronic inflammatory markers, which are believed to be a significant contributor to Treatment Resistant Depression. Under this Patent, GoodCap expects to obtain significant...

NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - June 30, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, is pleased to announce that it has entered into binding subscription agreements for a non-brokered private placement (the "Private Placement") of 10,150,000 units of the Company...

Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion

Lead drug candidate has shown superior and longer-lasting lowering of intraocular pressure, a risk factor associated with glaucoma, in preclinical studies

San Diego, California--(Newsfile Corp. - June 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion ("SBI-100 OE") from the Australian Human Research Ethics Committee ("HREC"). SBI-100 OE is a patented drug representing a new class of therapeutics to potentially treat glaucoma.The primary endpoints for...

Satellos Bioscience Announces In-Licensing of New Patent Application
Toronto, Ontario--(Newsfile Corp. - June 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has licensed a provisional patent application, recently filed with the United States Patent and Trademark Office and titled "MODULATION OF SATELLITE CELL POLARITY AND ASYMMETRIC CELL DIVISION," from the Ottawa Hospital Research Institute ("OHRI"). "This patent filing...

Subscribe to Biotech News